AIM: To identify characteristics of suboptimally controlled patients with type 2 diabetes (T2DM) on basal insulin treatment who may benefit from intensive titration or further intensification of treatment. METHODS: A post hoc analysis of SOLVE: a 24-week, international, observational study conducted in 17,374 patients with T2DM inadequately controlled on oral antidiabetic drugs (OADs) started on once-daily insulin detemir. Patients were divided into two groups based on whether they achieved HbA1c10years: 1.44 [1.17;1.77]; p2 OADs: 1.38 [1.14;1.66]; p=0.0003). Overall reporting of hypoglycemia was low; fewer patients with HbA1c⩾7.0% (⩾53.0mmol/mol) reported hypoglycemic events compared with patients with HbA1c<7.0% (9.8% vs. 12.5%, respectiv...
Background: The aim of the present study was to identify demographic and treatment factors that were...
Objective: For many patients with type 2 diabetes, oral antidiabetic agents (OADs) do not provide op...
OBJECTIVE: For many patients with type 2 diabetes, oral antidiabetic agents (OADs) do not provide op...
Aim: To identify characteristics of suboptimally controlled patients with type 2 diabetes (T2DM) on ...
AIMS: The aim of this analysis was to assess the efficacy and safety of intensifying insulin therapy...
OBJECTIVESTo evaluate the characteristics of patients with type 2 diabetes newly treated with basal ...
OBJECTIVESTo evaluate the characteristics of patients with type 2 diabetes newly treated with basal ...
Objective: To evaluate hospitalized type 2 diabetes mellitus (T2DM) patients with dissimilar insulin...
AIMS: To describe in a real-world setting the achievement of physician-selected individualized HbA1c...
BACKGROUND: When target glycated hemoglobin (HbA1C) levels are not reached, basal insulin therapy sh...
AIMS: To evaluate factors associated with reaching or not reaching target glycated haemoglobin (HbA1...
Introduction: Improving management practices and clinical outcomes in type 2 diabetes (IMPACT), was ...
This analysis investigated factors associated with the decrease in HbA1c in patients receiving conti...
Background: The aim of the present study was to identify demographic and treatment factors that were...
This analysis investigated factors associated with the decrease in HbA1c in patients receiving conti...
Background: The aim of the present study was to identify demographic and treatment factors that were...
Objective: For many patients with type 2 diabetes, oral antidiabetic agents (OADs) do not provide op...
OBJECTIVE: For many patients with type 2 diabetes, oral antidiabetic agents (OADs) do not provide op...
Aim: To identify characteristics of suboptimally controlled patients with type 2 diabetes (T2DM) on ...
AIMS: The aim of this analysis was to assess the efficacy and safety of intensifying insulin therapy...
OBJECTIVESTo evaluate the characteristics of patients with type 2 diabetes newly treated with basal ...
OBJECTIVESTo evaluate the characteristics of patients with type 2 diabetes newly treated with basal ...
Objective: To evaluate hospitalized type 2 diabetes mellitus (T2DM) patients with dissimilar insulin...
AIMS: To describe in a real-world setting the achievement of physician-selected individualized HbA1c...
BACKGROUND: When target glycated hemoglobin (HbA1C) levels are not reached, basal insulin therapy sh...
AIMS: To evaluate factors associated with reaching or not reaching target glycated haemoglobin (HbA1...
Introduction: Improving management practices and clinical outcomes in type 2 diabetes (IMPACT), was ...
This analysis investigated factors associated with the decrease in HbA1c in patients receiving conti...
Background: The aim of the present study was to identify demographic and treatment factors that were...
This analysis investigated factors associated with the decrease in HbA1c in patients receiving conti...
Background: The aim of the present study was to identify demographic and treatment factors that were...
Objective: For many patients with type 2 diabetes, oral antidiabetic agents (OADs) do not provide op...
OBJECTIVE: For many patients with type 2 diabetes, oral antidiabetic agents (OADs) do not provide op...